We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gene therapy company Passage Bio has launched in the US with $115.5m series A funding to develop AAV-delivered therapies for the treatment of rare monogenic central nervous system (CNS) disorders.....